HiSilicon: HSK46575 slice approved for clinical trial of prostate cancer treatment.

Huawei announced that its subsidiary, Liaoning Huawei Pharmaceutical Co., Ltd., has received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration. HSK46575 tablets have been approved for clinical trials for the treatment of prostate cancer. HSK46575 tablets are a self-developed oral, potent, and highly selective small molecule inhibitor intended for the treatment of prostate cancer. Preclinical studies have shown that the drug has a clear target, definite efficacy, and good safety profile, making it a promising small molecule drug with high potential for development. The benefits/risks ratio for clinical application is high, indicating broad prospects in clinical practices. It is expected to become an effective treatment for prostate cancer and address the current scarcity of clinical treatment options.